Medscape is available in 5 Language Editions – Choose your Edition here.


Brainstem Gliomas

  • Author: Joseph C Landolfi, DO; Chief Editor: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS  more...
Updated: Jun 09, 2016

Practice Essentials

Brainstem gliomas are tumors that occur in the region of the brain between the aqueduct of Sylvius and the fourth ventricle. Brainstem gliomas account for approximately 10-20% of all childhood brain tumors. The incidence in adults is lower than that in children younger than 16 years. See the image below.

T2-weighted image of a diffuse intrinsic pontine g T2-weighted image of a diffuse intrinsic pontine glioma.

Signs and symptoms

Common presenting signs and symptoms include the following:

  • Double vision
  • Weakness
  • Unsteady gait
  • Difficulty in swallowing
  • Dysarthria
  • Headache
  • Drowsiness
  • Nausea
  • Vomiting
  • Behavioral changes or seizures in children (rare)
  • Deterioration of handwriting and speech, in older children

Common clinical findings on physical examination can be summarized as constituting a triad of cranial nerve deficits, long tract signs, and ataxia (of trunk and limbs). Papilledema may be seen. Sixth and seventh cranial nerves are involved commonly. Facial sensory loss and a primary-position, upbeating nystagmus may be seen.

Certain manifestations suggest specific tumor locations, as follows:

  • Infants and children with failure to thrive – Pontine gliomas
  • Involvement of cranial nerve III or IV – A mesencephalic component
  • Hydrocephalus – Tumors in periaqueductal or fourth ventricle outflow locations

Patients with tectal lesions may present with the following:

  • Headache, nausea, and vomiting
  • Diplopia
  • Parinaud syndrome

Patients with cervicomedullary lesions may present with the following:

  • Dysphagia, unsteadiness, nasal speech, vomiting, and weakness
  • Sensory loss in the face (involvement of the trigeminal nucleus)
  • Dysphagia and/or dysphonia from lower cranial nerve involvement (commonly IX and X)
  • Long tract signs
  • Ataxia
  • Downbeating nystagmus and oculomyoclonus (medullary involvement)

See Clinical Presentation for more detail.


The workup for brainstem gliomas may include the following:

  • MRI of the head – Diagnostic test of choice
  • CT scan – Less accurate than MRI, but appropriate when MRI is not available
  • CSF examination – Often important for differential diagnosis
  • Arteriography – Occasionally useful in differentiating vascular lesions, including tumors, from gliomas

Lab studies of blood chemistry and related body fluids are not helpful as a rule. Tissue confirmation is frequently not feasible.

See Workup for more detail.


Treatment of brainstem gliomas may comprise the following:

  • Focal radiotherapy [1]
  • Chemotherapy
  • Surgical resection

Observation alone may be considered for some adult patients with any of the following:

  • A tectal lesion
  • A cervicomedullary lesion
  • Mild symptoms of long duration

Focal radiotherapy

  • The cornerstone of treatment of brainstem gliomas
  • Can improve or stabilize the patient's condition
  • Should be administered to any patient with significant and progressive neurologic symptoms
  • The conventional dose of radiotherapy ranges from 54-60 Gy, with doses up to 72 Gy given with hyperfractionation
  • Reported survival rates with radiation therapy are better in patients with exophytic tumors


  • Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas [2]
  • Postradiotherapy adjuvant chemotherapy cannot be recommended
  • Chemotherapy at relapse may benefit some patients
  • Chemotherapy may include conventional agents such as temozolomide and carboplatin/vincristine
  • Antiangiogenesis agents (eg, thalidomide, bevacizumab) have been used with success in supratentorial glioblastomas
  • If chemotherapy is desired adjuvantly or concurrently with radiotherapy, particularly in the pediatric population, consider entering the patient into a clinical trial

Surgical resection

Surgical therapy is performed in conjunction with radiation therapy, chemotherapy, or both. It is not required for diagnosis or treatment of diffuse intrinsic pontine or tectal gliomas; it is most appropriate in the following cases:

  • Tumors of the cervicomedullary junction
  • Dorsal exophytic tumors protruding into the fourth ventricle
  • Cystic tumors
  • Enhancing tumors with clear margins that exert a space-occupying effect
  • Benign tumors (ie, those with slow clinical progression)

See Treatment and Medication for more detail.



Brainstem gliomas are tumors that occur in the region of the brain referred to as the brain stem, which is the area between the aqueduct of Sylvius and the fourth ventricle. Although various systems are used to classify these tumors, the authors have divided brainstem gliomas into 3 distinct anatomic locations—diffuse intrinsic pontine,[3] tectal, and cervicomedullary. Intrinsic pontine gliomas carry a grave prognosis. Longer survival is associated with the tectal and cervicomedullary gliomas. Tumors also are characterized on the basis of site of origin, focality, direction and extent of tumor growth, degree of brainstem enlargement, degree of exophytic growth, and presence or absence of cysts, necrosis, hemorrhage, and hydrocephalus.[4]



These tumors have a predilection to originate from the left side. Most are located in the pons; however, medulla and midbrain may be involved as well. Brainstem gliomas are highly aggressive brain tumors. Anatomic location determines the pathophysiological manifestation of the tumor. With tectal lesions, hydrocephalus may occur as a result of fourth ventricular compression. With pontine and cervicomedullary lesions, cranial nerve or long tract signs are observed commonly.

Histopathologically, brainstem gliomas can range from WHO Grade 1 to 4. Grade 1 is the juvenile pilocytic astrocytoma, Grade 2 is the diffuse astrocytoma, Grade 3 is the anaplastic astrocytoma, and grade 4 is the glioblastoma multiforme. The grading is based on the presence of nuclear atypia, vascular proliferation, mitoses, and necrosis. Typically, the necrosis is seen in Grade 4 (glioblastoma multiforme).

Molecular profiling is now an important part of glioma classification. An IDH1 mutation carries an improved prognosis over the IDH1 wildtype, no matter what the tumor grade. Codeletions of Chromosome 1p and 19q along with an IDH1 mutation indicates an oligodendroglioma in Grade 1-3 gliomas. For pediatric diffuse gliomas, a newly defined entity termed diffuse midline glioma, H3 K27M-mutant is characterized by K27M mutations in the histone H3 gene, a diffuse growth pattern and a midline location. This newly defined entity occurs primarilty in children, but can be seen in adults, and includes tumors previously referred to as diffuse intrinsic pontine glioma (DIPG).[5]

Although biopsy or resection is not typically performed on brainstem gliomas, vascular endothelial growth factor (VEGF) receptors are an important pathway in the invasion and growth of supratentorial glioblastomas by promoting the growth of new blood vessels. Epidermal growth factor receptors (EGFR) are present in 25% of glioblastomas and are important in the growth of these neoplasms as well. The presence of these receptors may aid in the response to various targeted therapies, as is discussed in Medical Care.



United States

Brainstem gliomas have been reported to make up 2.4% of all intracranial tumors in adults and 9.4% of intracranial tumors in children. Brainstem gliomas account for approximately 10-20% of all childhood brain tumors. The incidence in adults is lower than that in children younger than 16 years. A tendency for brainstem gliomas to follow a more indolent course in adults than in children has been noted; in adults, these tumors are more likely to be low grade and remain localized.



Morbidity is due to the location of the space-occupying lesion and compression of surrounding structures; because these structures regulate basic body functions of blood pressure, respiration, and swallowing as well as motor and sensory functions, compression can produce substantial neurological disability.

Sudden death can result from increased intracranial pressure and subsequent cerebral herniation. This may be a consequence either of edema induced by the tumor or of hemorrhage into the neoplasm.





Race-, sex-, and age-related demographics

CNS tumors vary in incidence by age, sex, ethnic group, and country, and also over time. How much of this variation is due to artifactual influences or etiologic differences has been the subject of many debates.

Some reports have suggested a slight male preponderance, whereas others have failed to observe any sex predilection.

Bimodal age distribution has been noted, with a peak incidence in the latter half of the first decade of life and a second peak in the fourth decade. Approximately three fourths of patients are younger than 20 years.

Neoplasms of the brain stem have been identified in children younger than 1 year.

Contributor Information and Disclosures

Joseph C Landolfi, DO Director of Neurology, New Jersey Neuroscience Institute; Director of Neuro-oncology, Medical Director, Gamma Knife Program, JFK Brain Tumor Center; Chairman, Institutional Review Board, JFK Health System; Medical Director of Neuro-oncology, Meridian Health System; Professor of Neurology, Seton Hall University School of Graduate Medical Education

Joseph C Landolfi, DO is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Received honoraria from Novacure for speaking and teaching; Received honoraria from Genetech for speaking and teaching.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Jorge C Kattah, MD Head, Associate Program Director, Professor, Department of Neurology, University of Illinois College of Medicine at Peoria

Jorge C Kattah, MD is a member of the following medical societies: American Academy of Neurology, American Neurological Association, New York Academy of Sciences

Disclosure: Nothing to disclose.

Chief Editor

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS Professor Emeritus of Neurology and Psychiatry, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Neuroscience Director, Department of Neurology, Crouse Irving Memorial Hospital

Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS is a member of the following medical societies: American College of International Physicians, American Heart Association, American Stroke Association, American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners Institute, National Association of Managed Care Physicians, American College of Physicians, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, Royal Society of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Edward L Hogan, MD Professor, Department of Neurology, Medical College of Georgia; Emeritus Professor and Chair, Department of Neurology, Medical University of South Carolina

Edward L Hogan, MD is a member of the following medical societies: Alpha Omega Alpha, Society for Neuroscience, American Society for Biochemistry and Molecular Biology, American Academy of Neurology, American Neurological Association, Phi Beta Kappa, Sigma Xi, Southern Clinical Neurological Society

Disclosure: Nothing to disclose.


Anita Venkataramana, MBBS Clinical Instructor, Department of Neurology, Division of Neuroimmunology/HIV, Johns Hopkins University

Disclosure: Nothing to disclose.

  1. Vesper J, Bölke B, Wille C, Gerber PA, Matuschek C, Peiper M, et al. Current concepts in stereotactic radiosurgery - a neurosurgical and radiooncological point of view. Eur J Med Res. 2009 Mar 17. 14(3):93-101. [Medline].

  2. Frappaz D, Schell M, Thiesse P et al. Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic pontine gliomas: Final results of BSG 98 prospective trial. Neuro Oncol. Aug/2008. 10(4):599-607. [Medline].

  3. Frazier JL, Lee J, Thomale UW, Noggle JC, Cohen KJ, Jallo GI. Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. J Neurosurg Pediatr. 2009 Apr. 3(4):259-69. [Medline].

  4. Ueoka DI, Nogueira J, Campos JC, Maranhão Filho P, Ferman S, Lima MA. Brainstem gliomas--retrospective analysis of 86 patients. J Neurol Sci. 2009 Jun 15. 281(1-2):20-3. [Medline].

  5. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun. 131(6):803-20. [Medline].

  6. Grau SJ, Rachinger W, Holtmannspoetter M, Herms J, Tonn JC, Kreth FW. Serial Stereotactic Biopsy of Brainstem Lesions in Adults Improves Diagnostic Accuracy Compared to MRI Only. J Neurol Neurosurg Psychiatry. 2009 Jun 10. [Medline].

  7. Raza S, Donach M. Bevacizumab in adult malignant brainstem gliomas. J Neurooncol. 2009 Jun 9. [Medline].

  8. Kaplan AM, Albright AL, Zimmerman RA, Rorke LB, Li H, Boyett JM, et al. Brainstem gliomas in children. A Children's Cancer Group review of 119 cases. Pediatr Neurosurg. 1996. 24(4):185-92. [Medline].

  9. Squires LA, Allen JC, Abbott R, Epstein FJ. Focal tectal tumors: management and prognosis. Neurology. 1994 May. 44(5):953-6. [Medline].

  10. Grigsby PW, Garcia DM, Simpson JR, et al. Prognostic factors and results of therapy for adult thalamic and brainstem tumors. Cancer. 1989 Jun 1. 63(11):2124-9. [Medline].

  11. Landolfi JC, Thaler HT, DeAngelis LM. Adult brainstem gliomas. Neurology. 1998 Oct. 51(4):1136-9. [Medline].

  12. Hamilton MG, Lauryssen C, Hagen N. Focal midbrain glioma: long term survival in a cohort of 16 patients and the implications for management. Can J Neurol Sci. 1996 Aug. 23(3):204-7. [Medline].

  13. Kesari S, Kim RS, Markos V, Drappatz J, Wen PY, Pruitt AA. Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases. J Neurooncol. 2008 Jun. 88(2):175-83. [Medline].

  14. Abbott R, Shiminski-Maher T, Epstein FJ. Intrinsic tumors of the medulla: predicting outcome after surgery. Pediatr Neurosurg. 1996 Jul. 25(1):41-4. [Medline].

  15. Albright AL, Guthkelch AN, Packer RJ, et al. Prognostic factors in pediatric brain-stem gliomas. J Neurosurg. 1986 Dec. 65(6):751-5. [Medline].

  16. Barkovich AJ, Krischer J, Kun LE, et al. Brain stem gliomas: a classification system based on magnetic resonance imaging. Pediatr Neurosurg. 1990-91. 16(2):73-83. [Medline].

  17. Cohen ME, Duffner PK. 2nd ed. Brain Tumors in Children: Principles of Diagnosis and Treatment. New York: Raven Press; 1994.

  18. Cohen ME, Duffner PK, Heffner RR, et al. Prognostic factors in brainstem gliomas. Neurology. 1986 May. 36(5):602-5. [Medline].

  19. Dunkel IJ, O'Malley B, Finlay JL. Is there a role for high-dose chemotherapy with stem cell rescue for brain stem tumors of childhood?. Pediatr Neurosurg. 1996. 24(5):263-6. [Medline].

  20. Edwards MS, Wara WM, Urtasun RC, et al. Hyperfractionated radiation therapy for brain-stem glioma: a phase I-II trial. J Neurosurg. 1989 May. 70(5):691-700. [Medline].

  21. Epstein F, Wisoff J. Intra-axial tumors of the cervicomedullary junction. J Neurosurg. 1987 Oct. 67(4):483-7. [Medline].

  22. Fenichel Gerald M. Clinical Pediatric Neurology: A Signs and Symptoms Approach. 3rd ed. Philadelphia: WB Saunders Company; 1997.

  23. Guiney MJ, Smith JG, Hughes P, et al. Contemporary management of adult and pediatric brain stem gliomas. Int J Radiat Oncol Biol Phys. 1993 Jan 15. 25(2):235-41. [Medline].

  24. Jallo GI, Biser-Rohrbaugh A, Freed D. Brainstem gliomas. Childs Nerv Syst. 2004 Mar. 20(3):143-53. [Medline].

  25. Kaye AH, Laws ER. Brain Tumors. New York: Churchill Livingstone; 1995.

  26. Milstein JM, Geyer JR, Berger MS, Bleyer WA. Favorable prognosis for brainstem gliomas in neurofibromatosis. J Neurooncol. 1989 Nov. 7(4):367-71. [Medline].

  27. Rosenblum RK. Brain stem glioma: two case studies. J Pediatr Oncol Nurs. 2005 Mar-Apr. 22(2):114-8. [Medline].

  28. Tokuriki Y, Handa H, Yamashita J, et al. Brainstem glioma: an analysis of 85 cases. Acta Neurochir (Wien). 1986. 79(2-4):67-73. [Medline].

  29. Walker DA, Liu J, Kieran M, Jabado N, Picton S, Packer R, et al. A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro Oncol. 2013 Apr. 15(4):462-8. [Medline]. [Full Text].

T2-weighted image of a diffuse intrinsic pontine glioma.
T2-weighted image of a right tectal glioma.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.